Global Blood Therapeutics Inc. (GBT) EPS Estimated At $-0.71; SOLOS ENDOSCOPY (SNDY) Shorts Increased By 100%

February 24, 2018 - By Ellis Scott

Analysts expect Global Blood Therapeutics Inc. (NASDAQ:GBT) to report $-0.71 EPS on March, 12.They anticipate $0.03 EPS change or 4.05% from last quarter’s $-0.74 EPS. After having $-0.66 EPS previously, Global Blood Therapeutics Inc.’s analysts see 7.58% EPS growth. The stock increased 0.32% or $0.2 during the last trading session, reaching $62.85. About 538,161 shares traded. Global Blood Therapeutics Inc. (NASDAQ:GBT) has risen 43.51% since February 24, 2017 and is uptrending. It has outperformed by 26.81% the S&P500.

SOLOS ENDOSCOPY INC (OTCMKTS:SNDY) had an increase of 100% in short interest. SNDY’s SI was 1,200 shares in February as released by FINRA. Its up 100% from 600 shares previously. The stock decreased 8.75% or $0.00035 during the last trading session, reaching $0.00365. About 153,800 shares traded. Solos Endoscopy, Inc. (OTCMKTS:SNDY) has 0.00% since February 24, 2017 and is . It has underperformed by 16.70% the S&P500.

Solos Endoscopy, Inc., a healthcare instrument company, develops and markets technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment, and management of disease and medical conditions. The company has market cap of $6,108. The companyÂ’s products include breast endoscopy systems; 3-chip and 1-chip camera systems; cameras and accessories; endoscopic instruments, such as dissectors, graspers, scissors, needle holders, fan retractors, cautery instruments, and insufflation needles; and illumination series products, including fiber optic cables, light port adapters, light sources, and replacement lamps. It currently has negative earnings. It also offers insufflators; laparoscopic instruments, such as general surgery, lymphadenectomy, gynecology, and thorascopy instruments; rigid scopes and accessories, including laparoscopes, operative scopes, cystoscopes, and scope trays; trocar and cannula sets, cannulas, trocars, reducer sleeves, and seals; video carts; instrument handles that include insulated handles and non-insulated handles; and veterinary instrumentation.

Among 5 analysts covering Global Blood Therapeutics (NASDAQ:GBT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Global Blood Therapeutics had 8 analyst reports since September 8, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Wedbush given on Tuesday, September 8. Wedbush maintained Global Blood Therapeutics Inc. (NASDAQ:GBT) rating on Tuesday, October 25. Wedbush has “Outperform” rating and $73 target. The stock has “Overweight” rating by JP Morgan on Wednesday, January 4. Empire maintained Global Blood Therapeutics Inc. (NASDAQ:GBT) rating on Friday, June 17. Empire has “Buy” rating and $58 target. Cowen & Co initiated Global Blood Therapeutics Inc. (NASDAQ:GBT) on Tuesday, September 8 with “Outperform” rating. The firm has “Neutral” rating by Goldman Sachs given on Tuesday, September 8. The company was initiated on Tuesday, September 8 by Morgan Stanley.

Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood disorders. The company has market cap of $2.89 billion. The Company’s lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. It currently has negative earnings. The firm is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>